Early Transjugular Intrahepatic Portosystemic Shunt TIPS Treatment for Advanced Liver Cancer with Portal Vein Tumor Clots Causing Gastrointestinal Bleeding

What this Trial Is About

Researchers are investigating advanced hepatocellular carcinoma HCC with main trunk portal vein tumor thrombus PVTT, a serious condition often leading to poor outcomes due to portal hypertension causing gastrointestinal bleeding. This study aims to provide clinical evidence on the use of early transjugular intrahepatic portosystemic shunt TIPS within 72 hours after acute variceal bleeding to reduce portal pressure and bleeding risk in this patient group. The study involves performing early TIPS within 72 hours after endoscopic hemostasis to alleviate portal hypertension caused by PVTT. Patients included have advanced HCC with certain limits on tumor number and metastases, and receive first-line systemic therapies such as Lenvatinib and PD-1 inhibitors. The procedure is studied to see if it can prevent bleeding and improve survival outcomes. Participants will be monitored for technical success of the TIPS procedure at 3 months, rates of gastrointestinal bleeding at 6 months, and progression-free and overall survival up to 12 months. Researchers will also assess tumor response and record any adverse events during the 12-month follow-up. The total study period includes treatment and outcome assessments to evaluate the safety and effects of early TIPS in this specific HCC population.

Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma